

## Variant: *NM\_007294.4(BRCA1):c.191G>A (p.Cys64Tyr)*

Version: 2.0

CA001262 [↗](#)

54400 (ClinVar) [↗](#)

**Gene:** BRCA1 ([HGNC:672](#))

**Condition:** BRCA1-related cancer predisposition ([MONDO:0700268](#))

**Inheritance Mode:** Autosomal dominant inheritance

**UUID:** aed4706a-e502-48b4-8417-bb5c3aa01461

**Approved on:** 2024-06-12

**Published on:** 2024-06-11

### *HGVS expressions*

#### **NM\_007294.4:c.191G>A**

NM\_007294.4(BRCA1):c.191G>A (p.Cys64Tyr)

NC\_000017.11:g.43106477C>T

CM000679.2:g.43106477C>T

NC\_000017.10:g.41258494C>T

CM000679.1:g.41258494C>T

NC\_000017.9:g.38512020C>T

NG\_005905.2:g.111507G>A

ENST00000354071.8:n.255G>A

ENST00000461574.2:c.191G>A

ENST00000470026.6:c.191G>A

ENST00000473961.6:c.191G>A

ENST00000476777.6:c.191G>A

ENST00000477152.6:c.135-1521G>A

ENST00000478531.6:c.191G>A

ENST00000489037.2:c.135-1521G>A

ENST00000493919.6:c.50G>A

ENST00000494123.6:c.191G>A

ENST00000497488.2:c.-218-11617G>A

ENST00000618469.2:c.191G>A

ENST00000634433.2:c.191G>A

ENST00000644379.2:c.191G>A

ENST00000644555.2:c.50G>A

ENST00000652672.2:c.50G>A

ENST00000484087.6:c.191G>A

ENST00000700182.1:c.135-1521G>A

ENST00000700183.1:c.\*126+1G>A

ENST00000700184.1:n.434G>A

ENST00000357654.9:c.191G>A

ENST00000471181.7:c.191G>A

ENST00000642945.1:c.\*65G>A

ENST00000644555.1:c.50G>A

ENST00000652672.1:c.50G>A

ENST00000352993.7:c.191G>A

ENST00000354071.7:c.191G>A

ENST00000357654.7:c.191G>A

ENST00000461221.5:c.190+1G>A

ENST00000461798.5:c.190+1G>A  
ENST00000468300.5:c.191G>A  
ENST00000470026.5:c.191G>A  
ENST00000471181.6:c.191G>A  
ENST00000476777.5:c.191G>A  
ENST00000477152.5:c.135-1521G>A  
ENST00000478531.5:c.191G>A  
ENST00000489037.1:c.135-1521G>A  
ENST00000491747.6:c.191G>A  
ENST00000492859.5:c.\*127G>A  
ENST00000493795.5:c.50G>A  
ENST00000493919.5:c.50G>A  
ENST00000494123.5:c.191G>A  
ENST00000497488.1:c.-218-11617G>A  
ENST00000586385.5:c.4+18705G>A  
ENST00000591534.5:c.-44+18794G>A  
ENST00000591849.5:c.-99+18794G>A  
ENST00000634433.1:c.191G>A  
NM\_007294.3:c.191G>A  
NM\_007297.3:c.50G>A  
NM\_007298.3:c.191G>A  
NM\_007299.3:c.191G>A  
NM\_007300.3:c.191G>A  
NR\_027676.1:n.351+1G>A  
NM\_007297.4:c.50G>A  
NM\_007299.4:c.191G>A  
NM\_007300.4:c.191G>A  
NR\_027676.2:n.392+1G>A

**Pathogenic**

Met criteria codes **4**

PS3 PP4\_Strong PP3  
PM2\_Supporting

Evidence Links **1**

Expert Panel

[ENIGMA BRCA1 and BRCA2 VCEP](#)

Criteria Specification Information

- [Criteria Specification:](#) *ClinGen ENIGMA BRCA1 and BRCA2 Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for BRCA1 Version 1.0.0*
- [Criteria Specification Approval History](#)
- [Criteria Specifications for this VCEP](#)










Evidence submitted by expert panel

#### **ENIGMA BRCA1 and BRCA2 VCEP**

The c.191G>A variant in BRCA1 is a missense variant predicted to cause substitution of Cysteine by Tyrosine at amino acid 64 (p.Cys64Tyr). This variant is absent from gnomAD v2.1 (exomes only, non-cancer subset, read depth  $\geq 25$ ) and gnomAD v3.1 (non-cancer subset, read depth  $\geq 25$ ) (PM2\_Supporting met). This BRCA1 missense variant is within a key functional domain and the computational predictor BayesDel (noAF) gives a score of 0.557, above the recommended threshold of 0.28 for prediction of impact on BRCA1 function via protein change. SpliceAI predictor score of 0.00 suggests that the variant has no impact on splicing (score threshold  $< 0.10$ ) (PP3 met). Reported by one calibrated study to exhibit protein function similar to pathogenic control variants (PMID: 30209399) (PS3 met). Multifactorial

likelihood ratio analysis using clinically calibrated data produced a combined LR for this variant of 17239845573264 (based on Cosegregation LR=5300394; Pathology LR=189; Family History LR=17201), above the threshold for Very strong evidence towards pathogenicity (>350) (PP4\_Very strong met; PMID: 31131967, 31853058). In summary, this variant meets the criteria to be classified as a Pathogenic variant for BRCA1-related cancer predisposition based on the ACMG/AMP criteria applied as specified by the ENIGMA BRCA1/2 VCEP (PM2\_Supporting, PP3, PS3, PP4\_Very strong).

#### Met criteria codes

<b>PS3</b>	 	Reported by one calibrated study to exhibit protein function similar to pathogenic control variants (PMID: 30209399) (PS3 met).
		Deleterious <a href="#">PubMed:30209399</a> 
<b>PP4_Strong</b>	 	Multifactorial likelihood ratio analysis using clinically calibrated data produced a combined LR for this variant of 17239845573264 (based on Cosegregation LR=5300394; Pathology LR=189; Family History LR=17201), above the threshold for Very strong evidence towards pathogenicity (>350) (PP4_Very strong met; PMID: 31131967).
<b>PP3</b>	 	This BRCA1 missense variant is within a key functional domain and the computational predictor BayesDel (noAF) gives a score of 0.557, above the recommended threshold of 0.28 for prediction of impact on BRCA1 function via protein change. SpliceAI predictor score of 0.00 suggests that the variant has no impact on splicing (score threshold <0.10) (PP3 met).
<b>PM2_Supporting</b>	 	This variant is absent from gnomAD v2.1 (exomes only, non-cancer subset, read depth $\geq 25$ ) and gnomAD v3.1 (non-cancer subset, read depth $\geq 25$ ) (PM2_Supporting met).

#### Curation History

Showing 1 to 3 of 3 rows

--

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.